Back to search

Article

A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concern

2021-11-17

Abstract excerpt

<h4>Background</h4> CoronaVac ® is an inactivated SARS-CoV-2 vaccine approved by the World Health Organization. Previous studies reported increased levels of neutralizing antibodies and specific T cells two- and four-weeks after two doses of CoronaVac ® , but the levels of neutralizing antibodies are reduced at six to eight months after two doses. Here we report the effect of a booster dose of CoronaVac ® on the a...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
33961bda-5491-591e-9f98-0faa7c72e96c
DOI
10.1101/2021.11.16.21266350
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A booster dose of an inactivated SARS-CoV-2 vaccine increases neutralizing antibodies and T cells that recognize Delta and Omicron variants of concernDOI 10.1101/2021.11.16.21266350
Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac VaccinationSemantic proximity
The Efficacy for the Booster Dose of Covid-19 Vaccine between Sars-Cov-2 Omicron Variant and a Two-Year Longitudinal Antibody on Wild Type ConvalescentsSemantic proximity
Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac VaccinationSemantic proximity
Humoral and cellular response induced by a second booster of an inactivated SARS-CoV-2 vaccine in adultsSemantic proximity
The Third Dose of the SARS-CoV-2 Vaccine: Why and for Whom?Semantic proximity
Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 StudySemantic proximity
The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variantsSemantic proximity
Differential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trialSemantic proximity
Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 S antibodiesSemantic proximity
In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variantSemantic proximity
Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using two-dose primary protocol in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow upSemantic proximity
Inactivated vaccine fueled adaptive immune responses to Omicron in 2-year COVID-19 convalescentsSemantic proximity
Select a neighboring publication to make it the new centre.